3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
Key PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in...
Read moreKey PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in...
Read moreKey PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in...
Read moreKey PointsEven if it’s not being officially reported yet, its drug Casgevy is accruing revenue that will show up in...
Read more11 min read20 September Entrepreneur, papal knight and now Liberal Democrat backbencher Angus MacDonald tells Sienna...
Read moreAMC Robotics announced it has entered into a $50 million standby equity purchase agreement to help fund construction and commissioning...
Read moreKey PointsZoom Communications owns a stake in Anthropic worth billions.Zoom's underlying business is performing well. After subtracting out the values...
Read moreCrude oil prices retreated on Friday, with Brent and West Texas Intermediate (WTI) both slipping below their monthly highs. WTI...
Read moreThe S&P 500 Index ($SPX) (SPY) closed up by +0.17% on Friday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down by -0.18%,...
Read moreFor decades, CVS seemed like the perfect business. It was convenient, sold a mix of products people wanted, and everyone...
Read moreWelcome to the inaugural edition of Kernel Panic! A weekly newsletter by Lily Hay Newman and Matt Burgess from inside...
Read moreA crypto market rally is happening today, September 19, with Bitcoin and top altcoins like Ethena (ENA), Injective (INJ), and...
Read moreAn artificial intelligence (AI) chip can perform astonishing calculations. Yet without electricity, it becomes an exceptionally expensive desk ornament. That’s...
Read moreCopyright © 2026 investstrategiesgroup.com | All Rights Reserved